The Cancer Issue — PyRxia Therapeutics, Inc.

The Cancer Issue

Refractory Metastatic Cancer Has No Good Answers

Millions of patients exhaust standard therapies with survival measured in weeks to months — and the population at risk is far larger than mortality alone suggests.

United States

2.1M

New cancer diagnoses in the U.S. each year — the true addressable population, not just those with advanced or terminal disease.

~626K

U.S. cancer deaths per year, many following exhaustion of standard-of-care options for refractory disease.

Worldwide

20.6M

New cancer cases diagnosed globally each year — roughly 1 in 5 people will develop cancer in their lifetime.

9.8M

Cancer deaths worldwide per year, underscoring the scale of unmet need beyond the U.S. market alone.

No Tumor-Individualized Thermal Control

Conventional approaches rely on a single fixed treatment setpoint. Tumor microenvironments vary dramatically, yet no system measures or responds to real intratumoral conditions.

No Immune-Window Timing

Hyperthermal therapy creates a peak immunosensitization window — but no existing system detects it in real time or times immunotherapy delivery to it.

No Selective Toxin Removal

Current approaches strip both harmful metabolites and the immune-potentiating signals needed for a robust anti-tumor response.

Treatment Ends at Discharge

Post-treatment immune activation can persist for days — a therapeutic window that current approaches waste entirely.

Sources: American Cancer Society, Cancer Facts & Figures 2026 (~2.1M new U.S. cases, ~626,000 U.S. deaths projected for 2026); Siegel RL, et al., "Cancer Statistics, 2026," CA: A Cancer Journal for Clinicians; IARC/GLOBOCAN, Global Cancer Statistics 2024 (20.6M new cases, 9.8M deaths worldwide; ~1 in 5 lifetime risk); Bray F, et al., "Global Cancer Statistics 2024," CA: A Cancer Journal for Clinicians; World Health Organization, "Global Cancer Burden Growing, Amidst Mounting Need for Services".